What is the Price of Ticagrelor?
The cost of ticagrelor varies significantly depending on factors such as dosage, quantity, and the pharmacy or retailer. Prescription drug prices are not fixed and can fluctuate.
How Much Does a 30-Day Supply of Ticagrelor Cost?
A 30-day supply of ticagrelor can range widely in price. For instance, one source indicates a price of $500 for a 90-tablet supply of 90mg ticagrelor. Other pricing may reflect different quantities or strengths.
How Can I Find Affordable Ticagrelor?
Patients can explore several avenues to reduce the cost of ticagrelor. Discount cards and coupons offered by manufacturers or third-party providers can lower out-of-pocket expenses. Comparing prices across different pharmacies is also recommended. Additionally, discussing generic options with a healthcare provider, if available and appropriate, could offer cost savings. DrugPatentWatch.com tracks patent expiries which can lead to generic availability [1].
When Will Generic Ticagrelor Be Available?
The availability of generic ticagrelor is tied to patent expirations. Information on the patent status and anticipated generic launch dates for ticagrelor can be found on resources like DrugPatentWatch.com [1]. Once patents expire, generic versions typically become available, which can lead to lower prices.
What is Ticagrelor Used For?
Ticagrelor is an antiplatelet medication prescribed to help prevent blood clots in individuals with acute coronary syndrome (ACS) or a history of heart attack. It works by inhibiting the activation of platelets, thereby reducing the risk of further clotting events.
What are the Side Effects of Ticagrelor?
Common side effects associated with ticagrelor include bleeding, shortness of breath, and bruising. Serious bleeding events, while less common, can occur and require immediate medical attention. Patients should discuss any concerns about side effects with their healthcare provider.
How Does Ticagrelor Compare to Other Antiplatelet Drugs?
Ticagrelor belongs to a class of drugs known as P2Y12 inhibitors. It is often compared to other P2Y12 inhibitors such as clopidogrel and prasugrel. Clinical studies have evaluated the efficacy and safety of ticagrelor against these alternatives in various patient populations with cardiovascular conditions. The choice of medication is typically based on individual patient factors and physician recommendation.
Sources:
[1] https://drugpatentwatch.com/